Mannatech was featured in the Wall Street Journal last week, but it wasn’t because of it’s strong growth or product line, it was because of it’s continued medical claims related to their products. I didn’t read the article (it’s subscriber only) but I found a good summary at ScienceBlogs.com:

The practices of Mannatech distributors were the focus of a detailed article in this morning’s Wall Street Journal by Suzanne Sataline.

The Issue: Some consumers are using Mannatech nutritional supplements to seek relief from serious medical problems.

The Background: The company’s free-lance salespeople sometimes suggest
product uses that go well beyond recommendations on their labels.

What’s Next: The Texas attorney general is scrutinizing the company, which also faces a class-action lawsuit from shareholders.

Dietary supplements like those sold by Mannatech are, in general,
short on science and heavy on hype, anecdote, and testimonial. (Recall my earlier post where Nobel Laureate, Gunter Blobel, felt that his science was being misrepresented by the company.).

Some researchers says they doubt that [Mannatech’s]
Ambrotose offers any health benefits. Hudson Freeze, who studies
complex carbohydrates as a professor of glycobiology at the Burnham
Institute for Medical Research in La Jolla, Calif., contends the body
can’t digest Ambrotose because humans lack the enzymes necessary to
break down the plant fibers it contains into simple sugars.